Literature DB >> 18423937

PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.

Gregory S Harris1, Robert M Lust, Jonathan H DeAntonio, Laxmansa C Katwa.   

Abstract

Activation of PPAR-gamma through the administration of glitazones has shown promise in preserving function following cardiac injury, although recent evidence has suggested their use may be contraindicated in the case of severe heart failure. This study tested the hypothesis that PPAR-gamma expression increases in a time dependent manner in response to chronic volume overload (VO) induced heart failure. Additionally, we attempted to determine what effect 4 week administration of Urotensin II (UTII) may have on PPAR-gamma expression. VO induced heart failure was produced in Sprague-Dawley rats (n=32) by aorta-caval fistula. Animals were sacrificed at 1, 4, and 14 weeks following shunt creation. In a separate set of experiments, animals were administered 300 pmol/kg/h of UTII for 4 weeks, subjected to 4 weeks of volume overload, or given UTII+VO. Densitometric analysis of left ventricular (LV) protein demonstrated PPAR-gamma expression was significantly ((*)p<0.05) upregulated at 4 and 14 weeks (31.5% and 37%, respectively) post-fistula formation compared to control values. PPAR-gamma activation was decreased in the 4 and 14 week (39.16% and 42.4%, respectively), but not in the 1-week animals, and these changes did not correlate with NF-kappaB activity. Animals given UTII either with or without VO demonstrated increased expression of PPAR-gamma as did animals subjected to 4 week VO alone. Animals given UTII either with or without VO had decreased activity vs. control. These data suggest PPAR-gamma may play a role in the progression of heart failure, however, the exact nature has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423937      PMCID: PMC3876796          DOI: 10.1016/j.peptides.2008.03.001

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  29 in total

1.  Cardiostimulant effects of urotensin-II in human heart in vitro.

Authors:  F D Russell; P Molenaar; D M O'Brien
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.

Authors:  Tetsuya Shiomi; Hiroyuki Tsutsui; Shunji Hayashidani; Nobuhiro Suematsu; Masaki Ikeuchi; Jing Wen; Minako Ishibashi; Toru Kubota; Kensuke Egashira; Akira Takeshita
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

3.  Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

Authors:  Masayuki Asakawa; Hiroyuki Takano; Toshio Nagai; Hiroki Uozumi; Hiroshi Hasegawa; Naoto Kubota; Toshihiro Saito; Yoshiaki Masuda; Takashi Kadowaki; Issei Komuro
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

4.  Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism.

Authors:  F Liang; D G Gardner
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

5.  Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.

Authors:  T Tsuji; K Mizushige; T Noma; K Murakami; K Ohmori; A Miyatake; M Kohno
Journal:  J Cardiovasc Pharmacol       Date:  2001-12       Impact factor: 3.105

Review 6.  Thiazolidinedione-induced edema.

Authors:  Nancee V Niemeyer; Laurel M Janney
Journal:  Pharmacotherapy       Date:  2002-07       Impact factor: 4.705

7.  Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.

Authors:  Alex Tzanidis; Ross D Hannan; Walter G Thomas; Döne Onan; Dominic J Autelitano; Fiona See; Darren J Kelly; Richard E Gilbert; Henry Krum
Journal:  Circ Res       Date:  2003-07-03       Impact factor: 17.367

8.  Congestive heart failure and expression of myocardial urotensin II.

Authors:  Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

9.  Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

Authors:  Nicole S Wayman; Yoshiyuki Hattori; Michelle C McDonald; Helder Mota-Filipe; Salvatore Cuzzocrea; Babrbara Pisano; Prabal K Chatterjee; Christoph Thiemermann
Journal:  FASEB J       Date:  2002-07       Impact factor: 5.191

10.  Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.

Authors:  Satoshi Sakai; Takashi Miyauchi; Yoko Irukayama-Tomobe; Takehiro Ogata; Katsutoshi Goto; Iwao Yamaguchi
Journal:  Clin Sci (Lond)       Date:  2002-08       Impact factor: 6.124

View more
  2 in total

1.  Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias.

Authors:  John P Morrow; Alexander Katchman; Ni-Huiping Son; Chad M Trent; Raffay Khan; Takayuki Shiomi; Haiyan Huang; Vaibhav Amin; Joshua M Lader; Carolina Vasquez; Gregory E Morley; Jeanine D'Armiento; Shunichi Homma; Ira J Goldberg; Steven O Marx
Journal:  Circulation       Date:  2011-11-28       Impact factor: 29.690

Review 2.  Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.

Authors:  Pamela Lockyer; Jonathan C Schisler; Cam Patterson; Monte S Willis
Journal:  Mol Endocrinol       Date:  2009-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.